NICE (NICE) 2025 Investor Day June 17, 2025 02:00 PM ET Speaker0 So hello everyone, and, welcome to our Investor Day at Interactions twenty twenty five. My name is Marty Cohen. I'm head of Investor Relations at NICE, and I know most of you. So I hope you enjoyed the general session. And so I'm going what I want to do is just take you brief briefly through the agenda for the rest of the day, and, then we can begin. So for this session, we're gonna hear presentations from different members of our senior manag ...

Core Viewpoint - Nice (NICE) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2] Earnings Estimates and Stock Price Movement - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements [3] - Institutional investors utilize earnings estimates to calculate the fair value of a company's shares, leading to stock price movements based on their buying or selling activities [3] Business Improvement Indicators - The rising earnings estimates and the Zacks rating upgrade for Nice indicate an improvement in the company's underlying business, suggesting that investors may push the stock price higher [4] Importance of Earnings Estimate Revisions - Empirical research shows a strong correlation between earnings estimate revisions and near-term stock movements, making tracking these revisions beneficial for investment decisions [5] - The Zacks Rank stock-rating system effectively utilizes earnings estimate revisions to classify stocks into five groups, with a proven track record of performance [6] Specifics on Nice's Earnings Estimates - Nice is expected to earn $12.37 per share for the fiscal year ending December 2025, with no year-over-year change, while the Zacks Consensus Estimate has increased by 1.7% over the past three months [7] Zacks Rating System Overview - The Zacks rating system maintains a balanced proportion of "buy" and "sell" ratings across its universe of over 4,000 stocks, with only the top 20% receiving favorable ratings [8][9] - The upgrade of Nice to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9]

Core Viewpoint - Nice (NICE) has shown a positive stock performance recently, with a +7% return over the past month, outperforming the S&P 500 composite's +6.3% and the Zacks Internet - Software industry's +14.2% [1] Earnings Estimates - Nice is expected to report earnings of $2.99 per share for the current quarter, reflecting a year-over-year increase of +13.3% [4] - The consensus earnings estimate for the current fiscal year is $12.37, indicating a change of +11.2% from the previous year [4] - For the next fiscal year, the consensus estimate is $13.43, showing an increase of +8.6% compared to the prior year [5] - Over the last 30 days, the earnings estimates have changed positively by +2.4% for the current quarter and +2.2% for the current fiscal year [4][5] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $713.93 million, representing a year-over-year change of +7.5% [10] - The revenue estimates for the current and next fiscal years are $2.93 billion and $3.11 billion, indicating changes of +7% and +6.3%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Nice achieved revenues of $700.19 million, a year-over-year increase of +6.2%, and an EPS of $2.87 compared to $2.58 a year ago [11] - The company exceeded the Zacks Consensus Estimate for revenues by +0.12% and for EPS by +1.06% [11] - Nice has consistently beaten consensus EPS and revenue estimates in the last four quarters [12] Valuation - Nice's valuation is assessed using various multiples, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to determine if the stock is fairly valued [13][14] - The Zacks Value Style Score for Nice is graded C, indicating that it is trading at par with its peers [16] Bottom Line - The current Zacks Rank for Nice is 3 (Hold), suggesting that it may perform in line with the broader market in the near term [17]

Core Viewpoint - The article compares two stocks, Nice (NICE) and VERRA MOBILITY CORP (VRRM), to determine which is more attractive to value investors, highlighting NICE's stronger earnings outlook and better valuation metrics [1][3]. Valuation Metrics - NICE has a forward P/E ratio of 13.38, while VRRM has a forward P/E of 18.04, indicating that NICE may be undervalued compared to VRRM [5]. - The PEG ratio for NICE is 1.21, suggesting a favorable valuation relative to its expected earnings growth, whereas VRRM's PEG ratio is higher at 2.04 [5]. - NICE's P/B ratio stands at 2.99, significantly lower than VRRM's P/B of 12.57, further supporting NICE's position as a more attractive value option [6]. Earnings Outlook - NICE is noted for having an improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, suggesting it is a superior value option compared to VRRM [7].

Group 1 - NICE has reached a significant support level and recently broke through the 200-day moving average, indicating a long-term bullish trend [1] - The 200-day simple moving average is a widely-used indicator that helps establish market trends, and NICE has rallied 7.3% over the past four weeks, currently holding a Zacks Rank 3 (Hold) [2] - Positive earnings estimate revisions further strengthen the bullish case for NICE, with no estimates going lower in the past two months and 10 estimates increasing [3] Group 2 - The consensus estimate for NICE has increased, suggesting potential for further gains in the near future [3]

Nice (NICE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this software company have returned +7.3% over the past month versus the Zacks S&P 500 composite's +6.4% change. The Zacks Internet - Software industry, to which Nice belongs, has gained 12% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or rumors ab ...

Core Insights - NICE has recommended sparsentan as the first non-immunosuppressive dual-action therapy for primary IgA nephropathy in eligible patients, marking a significant advancement in treatment options [1][2][3] - The recommendation is based on the positive results from the Phase 3 PROTECT trial, which demonstrated sparsentan's efficacy in reducing proteinuria compared to irbesartan [1][8] Company Overview - CSL Vifor is a global partner specializing in pharmaceuticals and innovative therapies, particularly in iron deficiency and nephrology, with a focus on strategic global partnerships and precision healthcare [3][4] - The company plans to launch sparsentan in the UK in the second half of 2025, with commercial stock expected to be available from July 2025 [2][6] Industry Context - IgA nephropathy is the most common type of primary glomerular disease worldwide, affecting over 22,000 adults in England, with a significant risk of kidney failure if not adequately treated [2][5] - Current treatment guidelines indicate that patients with persistent urine protein excretion greater than 1 g/day are at high risk for progressive chronic kidney disease, highlighting the need for effective therapies like sparsentan [2][5][8] Clinical Trial Insights - The PROTECT trial involved 404 patients and showed that sparsentan achieved a mean reduction in proteinuria of 49.8% after 36 weeks, compared to 15.1% for irbesartan [8] - The trial was notable for being one of the largest interventional studies in IgA nephropathy and the only head-to-head trial in this area [8] Regulatory Milestones - The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for sparsentan in April 2025, paving the way for its use in the NHS [1][3] - NICE's guidance mandates that sparsentan must be funded within 90 days of the final publication, expected on June 27, 2025 [1][2]

I wrote about NICE Ltd. (NASDAQ: NICE ) ( OTCPK:NCSYF ), with their CCaaS (Contact Center as a Service) and FCC (Financial Crime and Compliance) software, at the beginning of February. I found it a compelling case, with the stock Analyst's Disclosure: I/we have a beneficial long position in the shares of NICE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I h ...

Core Viewpoint - NICE Ltd. is perceived as an undervalued cloud-native software solutions company, with strong performance indicated by rising cloud revenue in Q1 2025 [1] Company Performance - The Q1 2025 results demonstrated an overall strong performance for NICE Ltd. [1] - Cloud revenue showed significant growth, contributing to the company's positive financial outlook [1] Analyst Background - The analysis is conducted by a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management [1] - The analyst specializes in equity valuation, market trends, and portfolio optimization, focusing on identifying high-growth investment opportunities [1]

Core Insights - NICE reported adjusted earnings of $2.87 per share for Q1 2025, exceeding the Zacks Consensus Estimate by 1.06% and reflecting an 11% year-over-year increase [1] - Non-GAAP revenues reached $700.2 million, surpassing the consensus mark by 0.12% and showing a 6% year-over-year growth [1] Revenue Breakdown - Revenues in the Americas were $590 million, up 6% year over year [2] - EMEA revenues were $74 million, reflecting a 10% year-over-year increase [2] - APAC revenues increased by 9% year over year to $36 million [2] - Cloud revenues constituted 75.2% of total revenues at $526.3 million, marking a 12% year-over-year growth despite missing the consensus estimate by 0.22% [3] - Service revenues accounted for 20% of total revenues at $140.2 million, down 5.8% year over year and missing the consensus by 0.44% [3] - Product revenues, making up 4.8% of total revenues, were $33.7 million, exceeding the consensus by 8.31% but down 19.8% year over year [4] Operating Performance - Non-GAAP gross margin contracted by 100 basis points to 69.9% [5] - Research and development expenses as a percentage of revenues decreased by 60 basis points to 12.7% [5] - Sales and marketing expenses as a percentage of revenues contracted by 40 basis points to 23.1% [5] - General and administrative expenses decreased by 110 basis points to 9.9% [5] - Non-GAAP operating expenses as a percentage of revenues contracted by 120 basis points to 39.4% [6] - Non-GAAP operating margin expanded by 20 basis points to 30.5% [6] - Non-GAAP EBITDA margin increased by 30 basis points to 33.6% [6] Balance Sheet and Cash Flow - As of March 31, 2025, NICE had cash and cash equivalents of $1.61 billion, slightly down from $1.62 billion at the end of 2024 [7] - Long-term debt was $459.2 million, a slight increase from $458.8 million at the end of 2024 [8] - Cash flow from operations in Q1 2025 was $285.1 million, up from $249.5 million in the same quarter last year [8] - The company allocated $500 million for share repurchases in Q1 2025 [8] Guidance - For Q2 2025, NICE expects non-GAAP revenues between $709 million and $719 million, indicating a 7% year-over-year growth at the midpoint [9] - Non-GAAP earnings are projected to be between $2.93 and $3.03 per share, suggesting a 13% year-over-year growth at the midpoint [9] - For the full year 2025, NICE anticipates non-GAAP revenues between $2.92 billion and $2.94 billion, implying a 7% year-over-year growth at the midpoint [9] - Non-GAAP earnings for the full year are estimated to be between $12.28 and $12.48 per share, indicating an 11% year-over-year growth at the midpoint [10]